HCPLive

Top Medical News Today

Too Many Pills, Too Little Therapy for Youngest ADHD Kids
Half of very young children with ADHD are treated with medication rather than the behavioral modification that the American Academy of Pediatrics has recommended as first-line treatment, a CDC report finds.
This year at HRS, there has been a huge focus placed on social media and the power of communication within the digital space.
Certolizumab pegol is a safe alternative tumor necrosis factor-a inhibitor (TNFi) which may offer a few benefits to psoriatic arthritis
As officials continue to investigate the death of Prince Rogers Nelson at the age of 57, talk of a prescription drug addiction has been in the forefront.
Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.
Looking to become the latest addition to the field of treatment options for multiple sclerosis Zinbryta continues to show positive results during clinical trials as it awaits the final steps of the regulatory approval process in the United States and elsewhere.
A patch that uses patients’ own stem cells to protect them from vision loss will soon begin phase 1 trials.
Results from the ATLAS study show that patients with wet AMD treated with Eylea experienced visual and anatomic improvements after 1 year that were sustained after 2 years.
Phase 2a trial of novel topical anti-angiogenic agent regorafenib shows lack of efficacy in neovascular age-related macular degeneration.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$